Pushing the boundaries of imaging technology

We’re determined to push the boundaries of what imaging technology can achieve, to help develop next generation treatments with the potential to save or improve the lives of millions.

Clinical trial imaging

Harnessing the power of Imaging Phenomics

We’re transforming the science of medical imaging. By harnessing the power of Imaging Phenomics we can improve current treatment, enhance diagnosis and accelerate development of next generation therapies, helping make a healthier world for millions.

iBiopsy

We deliver on a global scale

The combination of Median’s ground-breaking technology and world-class expertise perfectly positions us to revolutionize the field of medical imaging, transforming data generation, management, and access all around the world. Benefiting patients, health professionals, our partners and investors.

Investors

Innovation is our DNA

Learn more about iSee®, our platform for the management of images in oncology clinical trials  and iBiopsy®, our imaging phenomics platform combining Artificial Intelligence, Cloud Computing and Big Data.

Watch

Latest press releases

4 May 2020

Liquidity Contract Transfer to Louis Capital Markets

Median Technologies is announcing that on March 30, 2020, it concluded a new liquidity contract with the Company Louis Capital Markets in accordance with the Amafi charter. The contract will take effect on the morning of May 4, 2020.

28 April 2020

Median records its best quarterly performance and joins forces with biopharmaceutical companies in the fight against Covid-19

Median Technologies (ALMDT), The Imaging Phenomics Company®, provides an update on its performance for Q1 2020 and a review of its commitment to tackle Covid-19. Revenue of €2.8m, +47% compared with the first quarter of 2019; Order backlog of €44.4m, +€6.1m compared with December 31, 2019; Median Technologies at the service of biopharmaceutical companies involved in Covid-19 clinical trials.

20 April 2020

Median Technologies receives a disbursement of €15 million, corresponding to the first tranche of the loan granted by the European Investment Bank

The disbursement improves the Company’s financial visibility. It will help accelerate the investment program for the iBiopsy® imaging platform developed by Median Technologies. The Company provides outlook for the iBiopsy® program for 2020.

14 April 2020

Median Technologies reports full year 2019 financial results

Median Technologies reports full year 2019 financial results: Revenue of €9m as of December 31, 2019, an increase of 41% compared with revenue for 2018; Order backlog of €38.3m, +61.6% compared with December 31, 2018; Cash and cash equivalents of €7.6m

2 March 2020

Assistance Publique – Hôpitaux de Paris (AP-HP) and Median Technologies reach a research collaboration agreement involving the iBiopsy® platform

Assistance Publique – Hôpitaux de Paris (AP-HP) and Median Technologies reach a research collaboration agreement involving the iBiopsy® platform. The collaboration agreement initially covers two joint clinical studies on liver cancer, involving coordinating investigators from two AP-HP hospitals -Pitié-Salpêtrière and Paul-Brousse-, and Median’s team. The agreement will enable Median to work with large patient cohorts for the clinical validation of iBiopsy®’s AI technologies.

1/5

Message from the CEO

Dear clients and partners,

As the COVID-19 continues to spread, our thoughts are with individuals and communities who have been most severely impacted by the disease and as well with the healthcare professionals who are working round the clock to help patients. We truly hope that you, your family, friends, and colleagues are safe and well and are taking the necessary precautions to keep it that way. As a company, Median Technologies has decided to have all employees work remotely for their own safety […]

Webinars

APRIL 21, 2020 05:00PM CEST

The Evolution of Response Evaluation Criteria in Cancer Immunotherapy

The response evaluation of cancer immunotherapy requires differentiation from traditional chemotherapy; hence, it needs more precise criteria that are compatible with the observed response patterns and the well-documented mechanism of action of these novel treatments. This 30 minutes presentation + 15 minutes Q&A provides a review of the latest advances of imaging assessment for cancer immunotherapy evaluation in clinical trials.

Imaging for clinical trials

Advancing treatments of the future

Working with biopharma companies and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments.

Read more

iBiopsy®

Powering the phenomics revolution

We’re changing the game, transforming the landscape. We’re capturing the power of big data, cloud computing and artificial intelligence to create a new world of possibilities for biopharma compannies and healthcare professionals alike. Our iBiopsy® platform opens up the field of phenomics, driving the science of precision and predictive medicine.

Read more

Investors

Delivering value

Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.

Read more

Stock Market Data

TICKER: ALMDT ISIN: FR0011049824
Get in touch

Together, let's build the future of medicine

Contact us Jobs at Median